Citigroup Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $32.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective reduced by equities researchers at Citigroup from $33.00 to $32.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective indicates a potential upside of 42.86% from the stock’s previous close.

A number of other research firms also recently weighed in on ACAD. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 3rd. Citizens Jmp raised their price target on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the company a “market outperform” rating in a research report on Thursday, February 26th. Bank of America upgraded ACADIA Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Wednesday, March 25th. Stifel Nicolaus lowered their price target on ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Thursday, February 26th. Finally, TD Cowen raised their price target on ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $31.00.

ACADIA Pharmaceuticals Price Performance

NASDAQ ACAD traded down $0.16 during trading hours on Friday, reaching $22.40. 2,081,199 shares of the stock traded hands, compared to its average volume of 1,726,507. The stock has a 50 day simple moving average of $22.06 and a two-hundred day simple moving average of $23.90. ACADIA Pharmaceuticals has a 1 year low of $16.76 and a 1 year high of $28.35. The company has a market cap of $3.84 billion, a price-to-earnings ratio of 10.18, a price-to-earnings-growth ratio of 22.40 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 10.23%. The firm had revenue of $268.10 million for the quarter, compared to analysts’ expectations of $280.25 million. During the same quarter in the previous year, the business earned $0.11 EPS. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, sell-side analysts forecast that ACADIA Pharmaceuticals will post 0.45 EPS for the current fiscal year.

Insider Activity

In other news, insider James Kihara sold 1,332 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $21.79, for a total transaction of $29,024.28. Following the transaction, the insider directly owned 29,129 shares of the company’s stock, valued at approximately $634,720.91. This trade represents a 4.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer J. Rhodes sold 6,950 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $23.38, for a total value of $162,491.00. Following the transaction, the executive vice president directly owned 7,609 shares in the company, valued at $177,898.42. This trade represents a 47.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 15,527 shares of company stock valued at $350,917. 26.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in shares of ACADIA Pharmaceuticals by 8.0% during the first quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock valued at $70,222,000 after buying an additional 234,186 shares during the last quarter. Swiss National Bank grew its stake in shares of ACADIA Pharmaceuticals by 0.6% in the first quarter. Swiss National Bank now owns 234,404 shares of the biopharmaceutical company’s stock worth $5,218,000 after purchasing an additional 1,500 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of ACADIA Pharmaceuticals by 21,126.8% in the first quarter. Bessemer Group Inc. now owns 150,498 shares of the biopharmaceutical company’s stock worth $3,350,000 after purchasing an additional 149,789 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of ACADIA Pharmaceuticals by 44.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 954,855 shares of the biopharmaceutical company’s stock worth $21,312,000 after purchasing an additional 296,042 shares during the last quarter. Finally, Illinois Municipal Retirement Fund grew its stake in shares of ACADIA Pharmaceuticals by 12.7% in the first quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock worth $1,585,000 after purchasing an additional 7,996 shares during the last quarter. 96.71% of the stock is owned by institutional investors.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Neutral Sentiment: ACADIA reported Q1 2026 earnings of $0.02 per share, below the $0.04 consensus, while revenue of $268.1 million also missed estimates. The company did still post 9.7% year-over-year revenue growth and reaffirmed its 2026 guidance. Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
• Neutral Sentiment: HC Wainwright kept a Buy rating and $37 price target, but trimmed several forward EPS estimates for ACADIA, including FY2026 to $0.37 from $0.46 and Q3 2026 to $0.13 from $0.16, reflecting a slightly more cautious outlook. Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (OtherKSPHF), Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)
• Neutral Sentiment: The firm also lowered longer-term earnings forecasts for FY2027, FY2028, FY2029 and FY2030, but the reductions were modest and the analyst still sees substantial profit growth over time.
• Negative Sentiment: The latest earnings miss and the analyst estimate cuts likely reinforce concerns that near-term profitability may be more uneven than investors expected, which can weigh on the stock. ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.